Tags : Detailed

AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF

Tuba Khan September 2, 2019

Shots: The P-III DAPA-HF study involves assessing of Farxiga (10mg) vs PBO in addition to SOC in patients with HF and reduced ejection fraction (LVEF ≤ 40%) with/out T2D The […]readmore

Tags : Detailed

AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Detailed

AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company